

Critical Pro–Con Questions Around the 2025 ATA Differentiated Thyroid Cancer Guidelines (ETA 2026 Pre-Congress Symposium)

Less Is More or Not Enough? A dissection of the 2025 ATA DTC Guidelines from an Iberian perspective

Date: 4th September 2026 14h00-18h00

**Meeting venue: i3S – Instituto de Investigação e Inovação em Saúde
Universidade do Porto auditorium Mariano Gago**

Program

- **Opening (15 min):** Brief overview of ATA 2025 scope, methods, and key innovations (DATA framework, 4-tier risk stratification, de-escalation).
 - Spanish speakers: Carles Zafon
- **Block I (40–45 min) :** Methodology and guidelines philosophy
 - Spanish speaker: Juan Carlos Galofré and Garcilaso Riesco
- **Block II (55–60 min):** Initial management—surgery, active surveillance, and early RAI; surgical and nuclear medicine viewpoints
 - Portuguese speaker: Cláudia Freitas and Francisca Puga
- **Coffee break (10–15 min)**
- **Block III (50–55 min) :** Long-term follow-up and survivorship (TSH targets, de-escalation, Tg after total thyroidectomy, dynamic risk stratification)
 - Spanish speaker: Cecília Sánchez and Pablo Valderrábano
- **Block IV (55–60 min)::** Advanced/RAIR DTC management (RAIR definition, sequencing lenvatinib vs selective inhibitors vs trials, molecular testing, redifferentiation/IO).
 - Portuguese speaker: Elisabete Rodrigues and Tiago Nunes da Silva
- **Closing:** Panel consensus statements on “where Iberian task force might align with or diverge from ATA 2025”

